Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 3Sturge-Weber Syndrome 2Neoplasms 2Nausea 2Marijuana Abuse 2Colonic Neoplasms 2Anxiety Disorders 2Vomiting 1Solid Tumor 1Parasomnias 1Pain 1Glioblastoma 1Dysgeusia 1Drug Resistant Epilepsy 1Colorectal Neoplasms 1Cognitive Dysfunction 1Chemotherapy-Induced Peripheral Neuropathy 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1Cachexia 1Breast Carcinoma In Situ 1Breast Cancer Female 1Arthralgia 1Appetitive Behavior 1

Interventions

perampanel 1Sirolimus 1Immunoglobulins, Intravenous 1Cannabidiol 1Anticonvulsants 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Drug Resistant Epilepsy × Cannabidiol × Clear all
NCT02332655 2022-03-02

Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Phase 1/2 Completed
5 enrolled 8 charts

Drug Resistant Epilepsy, Sturge-Weber Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡